SISVEL
7.1.2016 17:46:21 CET | Business Wire | Press release
Sisvel, a global licensing company that has been dedicated to patent licensing since its foundation in 1982, has announced today that it is going beyond traditional patent licensing in how it acquires and monetizes patent portfolios and partners with IP players.
Sisvel is now offering its IP commercialization platform to anyone who wishes to gain greater value from Intellectual Property. This platform allows both IP Buyers and Sellers to use Sisvel’s proven network of partners, expertise in licensing and technical analysis – something no other entity now offers.
“IP buyers and sellers are in dire need to be directed by a competent player in the marketplace,” said Karel van Lelyveld, CEO of the Sisvel Group. “Sisvel has been active in this market for more than 30 years and we know what it takes to find the proverbial needle in a haystack. With our new IP Commercialization Platform we now provide easy and immediate access to buyers and sellers who want to transact assets. Our platform provides the simplicity and transparency needed to take back the market for those who develop innovative technologies and those who are seeking to get IP protection for innovative solutions”.
IP Commercialization Platform Features:
- Match for IP: Sisvel’s IP platform bridges buyer and seller requests and helps both parties achieve efficient solutions.
- Marketing IP Correctly: Sisvel’s team can help a company structure and optimize its Intellectual Property (IP) portfolio as well as identify the right assets to monetize.
- Finding the Proverbial Needle in a Haystack: Companies from around the world can now find specific IP assets in technical areas of interest, from selected sellers and pre-qualified portfolio opportunities.
“With Sisvel in the mix, there is no need to run around to ten or twenty different firms trying to buy access to the technologies you may need,” said Chuck Hausman, Vice President of Sisvel US.
Sisvel will formally unveil its new worldwide IP commercialization platform at CES 2016 with an announcement during a private reception on Thursday, January 7 from 4-6 p.m in the LVCC South Hall, Booth #1-20306. Sisvel’s management team will be available at the event to discuss the new platform’s benefits.
RSVP and further information:
Veronica Pugi veronica.pugi@sisvel.com
Sue
Ellen Schaming sschaming@hoogcomm.com
About Sisvel
Started in 1982 when Sisvel S.p.A. was founded
in Italy, the Sisvel Group has become a world leader in managing
intellectual property and maximizing the value of patent rights. The
Sisvel Group is global in scope and reach, with subsidiaries in Italy
(Sisvel and Sisvel Technology in None Torinese), the United States
(Sisvel US and Audio MPEG in Metropolitan Washington, DC), China (Sisvel
Hong Kong), Japan (Sisvel Japan in Tokyo), Germany (Sisvel Germany in
Stuttgart), Luxembourg (Sisvel International), and the United Kingdom
(Sisvel UK), with over one hundred professionals worldwide with
engineers, legal, and licensing expertise. Sisvel has a long history of
managing successful patent portfolios including those related to the
audio compression standards known as MP3 and MPEG Audio, and widespread
technologies such as OSD (On Screen Display), ATSS (Automatic Tuning &
Sorting System), and WSS (Wide Screen Signalling - for automatic
switching of television image formats). Sisvel currently operates patent
pools and joint licensing programs for the DVB-T, DVB-T2, LTE/LTE-A and
Wi-Fi standards, together with its Sisvel Wireless licensing program and
is in the process of creating a new licensing program for DVB-C2.
For additional information, please visit: www.sisvel.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160107005959/en/
Contact:
Media Contact
Sisvel Group
Veronica Pugi, Tel: +
39 011 990 4114
Senior Communications Officer
veronica.pugi@sisvel.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom